The TPP negotiations, from pharma’s perspective
Representatives of innovator pharmaceutical companies see the Transpacific Partnership (TPP) as a means to not only strengthen protections in emerging IP regimes, but also a way to formalise and clarify laws in countries that already have strong protections
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: